CD71

Ryvu Therapeutics Presents Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Monday, December 11, 2023

Treatment continues to show a favorable safety profile with 50-70% target engagement achieved at a dose of 250 mg.

Key Points: 
  • Treatment continues to show a favorable safety profile with 50-70% target engagement achieved at a dose of 250 mg.
  • The published clinical and non-clinical data strongly support RVU120’s Phase II development plans presented in October.
  • KRAKOW, Poland, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Ryvu Therapeutics [WSE:RVU], a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, presents clinical and preclinical data on RVU120, a selective CDK8/19 inhibitor, at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition, which is held on December 9-12, 2023, in San Diego, California.
  • “The results from the CLI120-001 (RIVER-51) study of RVU120 in patients with r/r-AML and HR-MDS continue to improve over time.

CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 7, 2023

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today reported third quarter 2023 financial results and provided a business update.

Key Points: 
  • We have continued to diligently manage our financial resources and drive towards value-inflecting pipeline milestones,” said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX Therapeutics.
  • Preclinical profile of EpCAM-directed antibody drug conjugate CX-2051 presented at 2023 World ADC Conference – In October 2023, Dr. Marcia Belvin, chief scientific officer, CytomX Therapeutics, presented data characterizing the preclinical profile for CX-2051.
  • CX-2051 is tailored for treatment of EpCAM-expressing cancers by matching target expression and tumor sensitivity with a topoisomerase-1 inhibitor payload.
  • CytomX management will host a conference call and simultaneous webcast today at 5 p.m. EDT (2 p.m. PDT) to discuss the financial results and provide a business update.

CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, August 8, 2023

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today reported second quarter 2023 financial results and provided a business update.

Key Points: 
  • - Management to hold conference call today at 5 p.m. EDT / 2 p.m. PDT -
    SOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today reported second quarter 2023 financial results and provided a business update.
  • In the private placement, CytomX sold pre-funded warrants and accompanying tranche warrants at a combined price of $2.08 per share.
  • Yu-Waye (Wayne) Chu, M.D., joins CytomX as Chief Medical Officer – In July 2023, CytomX announced the appointment of Yu-Waye (Wayne) Chu, M.D., as Chief Medical Officer (CMO).
  • CytomX management will host a conference call and simultaneous webcast today at 5 p.m. EDT (2 p.m. PDT) to discuss the financial results and provide a business update.

Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2023 European Hematology Association Congress

Retrieved on: 
Friday, June 9, 2023

We anticipate the clinical benefit will even further increase as dose-escalation progresses in patients with AML and HR-MDS.

Key Points: 
  • We anticipate the clinical benefit will even further increase as dose-escalation progresses in patients with AML and HR-MDS.
  • Importantly, we observed that treatment with RVU120 induces erythropoiesis, which supports further testing in patients with anemia.
  • We are also encouraged to see that the monotherapy continues to be generally well-tolerated across all dose levels.
  • These data warrant further clinical development of RVU120 in combination with JAK1/2 inhibition as a potential novel therapeutic strategy in myeloproliferative neoplasms.

CytomX Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, May 9, 2023

“As we entered 2023, CytomX continued the advancement of our diversified portfolio of innovative Probody® therapeutic candidates for the treatment of cancer while ensuring disciplined resource allocation,” said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX Therapeutics.

Key Points: 
  • “As we entered 2023, CytomX continued the advancement of our diversified portfolio of innovative Probody® therapeutic candidates for the treatment of cancer while ensuring disciplined resource allocation,” said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX Therapeutics.
  • CX-904 is partnered with Amgen and is being evaluated by CytomX in an ongoing Phase 1 study in patients with advanced solid tumors.
  • CytomX and Astellas are collaborating on additional conditionally activated TCB programs, and CytomX is eligible to receive future preclinical, clinical, and commercial milestones.
  • ET (2 p.m. PT) to discuss the financial results and provide a business update.

CytomX Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Monday, March 27, 2023

“2022 was an important year of transition for CytomX as we proactively restructured our organization to maximize long-term success and value creation.

Key Points: 
  • “2022 was an important year of transition for CytomX as we proactively restructured our organization to maximize long-term success and value creation.
  • CX-904 is being evaluated by CytomX in an ongoing Phase 1 study in patients with advanced solid tumors.
  • The financial results contained in this press release reflect the restated financial statements in CytomX’s most recent SEC filings.
  • ET (2 p.m. PT) to discuss the financial results and provide a business update.

CytomX Therapeutics to Present Phase 2 Data for Praluzatamab Ravtansine (CX-2009) in Patients with Advanced Breast Cancer at the San Antonio Breast Cancer Symposium

Retrieved on: 
Wednesday, December 7, 2022

The poster details the results from patients treated with monotherapy praluzatamab ravtansine for the treatment of advanced HR+/HER2- breast cancer and triple negative breast cancer (TNBC).

Key Points: 
  • The poster details the results from patients treated with monotherapy praluzatamab ravtansine for the treatment of advanced HR+/HER2- breast cancer and triple negative breast cancer (TNBC).
  • “We thank our investigators and the patients and families who contributed to our comprehensive evaluation of praluzatamab ravtansine in breast cancer.
  • Praluzatamab ravtansine (CX-2009) is an investigational conditionally activated ADC directed toward CD166 that has demonstrated single agent clinical activity in a Phase 2 study for patients with advanced HR+/HER2-non-amplified breast cancer.
  • Following the Phase 2 results, CytomX decided not to further progress praluzatamab ravtansine alone and is seeking a partner to further develop the molecule.

CytomX Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 8, 2022

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today reported third quarter 2022 financial results and provided a business update.

Key Points: 
  • - Continued progress with Phase 2 collaborator programs CX-2029 (AbbVie, Phase 2)
    and BMS-986249 (Bristol Myers Squibb, Phase 2) -
    SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today reported third quarter 2022 financial results and provided a business update.
  • CytomXs progress in the third quarter highlights the potential of our pipeline as well as the breadth and versatility of the Probody platform.
  • A data update for the sqNSCLC cohort is expected in the fourth quarter of 2022.
  • ET (2:00 p.m. PT) to discuss the financial results and provide a business update.

CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b (CX-801) at the SITC 2022 Annual Meeting

Retrieved on: 
Monday, November 7, 2022

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that preclinical data for CX-801, its conditionally activated cytokine program, will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in Boston, Massachusetts.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that preclinical data for CX-801, its conditionally activated cytokine program, will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in Boston, Massachusetts.
  • Interferon alpha is a clinically validated, powerful antitumor agent, but has historically been limited in its clinical use due to toxicity.
  • At the upcoming SITC Annual Meeting, we will report encouraging preclinical data that support the development of CX-801 based on its single agent activity as well as its enhanced activity when combined with PD-L1 blockade.
  • We plan to explore the clinical potential of CX-801 in tumor types that have traditionally been both responsive and unresponsive to immunotherapy.

CytomX Therapeutics to Present at Upcoming November Investor Conferences

Retrieved on: 
Wednesday, November 2, 2022

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in the following investor conferences in November.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in the following investor conferences in November.
  • In addition, management will be available for one-on-one meetings with investors who are registered to attend the conferences.
  • CytomX has also established strategic collaborations with multiple leaders in oncology, including AbbVie, Amgen, Astellas, and Bristol Myers Squibb.
  • Probody is a U.S. registered trademark of CytomX Therapeutics, Inc.